<SEC-DOCUMENT>0001628280-22-021051.txt : 20220804
<SEC-HEADER>0001628280-22-021051.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804160424
ACCESSION NUMBER:		0001628280-22-021051
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220804
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		221136433

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ardx-20220804.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:1392da93-4cce-4f51-9204-96af2cb97a3b,g:1f19f9d2-6f60-4abd-b179-525c41c41081,d:d9493d6b320c43bc9334024787663dbd--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ardx-20220804</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF80L2ZyYWc6NGY1NGMzMzZhOTJhNGUwMWI2OTkyMGViZGU1NDZmYjIvdGFibGU6NTI1N2NhYTVhYmViNGFlODgyYzI0MWIwZGMxYzE1OTcvdGFibGVyYW5nZTo1MjU3Y2FhNWFiZWI0YWU4ODJjMjQxYjBkYzFjMTU5N18yLTEtMS0xLTM0NDg5_f58008ff-a9ce-4e69-8f84-935af6fe5857">0001437402</ix:nonNumeric><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF80L2ZyYWc6NGY1NGMzMzZhOTJhNGUwMWI2OTkyMGViZGU1NDZmYjIvdGFibGU6NTI1N2NhYTVhYmViNGFlODgyYzI0MWIwZGMxYzE1OTcvdGFibGVyYW5nZTo1MjU3Y2FhNWFiZWI0YWU4ODJjMjQxYjBkYzFjMTU5N18zLTEtMS0xLTM0NDg5_2771d50d-04d9-412f-a452-23fd9c15cd02">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ardx-20220804.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-04</xbrli:startDate><xbrli:endDate>2022-08-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id9493d6b320c43bc9334024787663dbd_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjYx_ac66504e-3b4e-49ef-b47c-4b9600169cda">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8yMzE_b973efd0-b09d-4b26-836f-d81350e71f28">August 4, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><img src="ardx-20220804_g1.jpg" alt="ardx-20220804_g1.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:75px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjU0_600fb92d-0917-428c-8e76-018848175759">ARDELYX, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6OTBmNTc2Mzk3ZTgzNDNiN2IzMTQ4ODI4NzZlNjQ5ODEvdGFibGVyYW5nZTo5MGY1NzYzOTdlODM0M2I3YjMxNDg4Mjg3NmU2NDk4MV8wLTAtMS0xLTM0NDg5_79a98c5a-c7b5-44da-b5a8-d68109127fb4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6OTBmNTc2Mzk3ZTgzNDNiN2IzMTQ4ODI4NzZlNjQ5ODEvdGFibGVyYW5nZTo5MGY1NzYzOTdlODM0M2I3YjMxNDg4Mjg3NmU2NDk4MV8wLTEtMS0xLTM0NDg5_b5cf26e1-5f21-496b-914e-29f8171430cd">001-36485</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6OTBmNTc2Mzk3ZTgzNDNiN2IzMTQ4ODI4NzZlNjQ5ODEvdGFibGVyYW5nZTo5MGY1NzYzOTdlODM0M2I3YjMxNDg4Mjg3NmU2NDk4MV8wLTItMS0xLTM0NDg5_bf809a2e-fc49-4996-a11c-607aa3f150e7">26-1303944</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjU2_b0070d5e-e3d7-4bb2-907f-7935f2e96d50">400 FIFTH AVE.</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjU3_7843159d-6cac-43a1-90c0-d4e40fcc91e2">SUITE 210</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjYy_e7acb292-af08-4c40-8b45-f3fef8d1fd0f">WALTHAM</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjYz_b2d6ab0f-d25e-4b97-9644-1d823f45a1a0">MA</ix:nonNumeric>SSACHUSETTS&#160;<ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjY0_b5059173-d643-4367-8ea2-3520d1c5c997">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including Zip Code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjU5_babbb14e-fa24-4d59-a8bd-4caeab27d88f">510</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjY1_f5b7125f-f52c-4db3-9a14-3dc129d5f50c">745-1700</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ODAxZmEwMTE4MzM3NDY2N2E2Yzg0OThlY2ZlYzA0NWYvdGFibGVyYW5nZTo4MDFmYTAxMTgzMzc0NjY3YTZjODQ5OGVjZmVjMDQ1Zl8wLTAtMS0xLTM0NDg5_655d760f-b946-4afd-80ea-314993414704">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ODAxZmEwMTE4MzM3NDY2N2E2Yzg0OThlY2ZlYzA0NWYvdGFibGVyYW5nZTo4MDFmYTAxMTgzMzc0NjY3YTZjODQ5OGVjZmVjMDQ1Zl8xLTAtMS0xLTM0NDg5_be9a9035-8ea4-43e1-a86c-547077b3255c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ODAxZmEwMTE4MzM3NDY2N2E2Yzg0OThlY2ZlYzA0NWYvdGFibGVyYW5nZTo4MDFmYTAxMTgzMzc0NjY3YTZjODQ5OGVjZmVjMDQ1Zl8yLTAtMS0xLTM0NDg5_5a0146d4-192b-44fc-985e-b42e71026533">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ODAxZmEwMTE4MzM3NDY2N2E2Yzg0OThlY2ZlYzA0NWYvdGFibGVyYW5nZTo4MDFmYTAxMTgzMzc0NjY3YTZjODQ5OGVjZmVjMDQ1Zl8zLTAtMS0xLTM0NDg5_b32c61e1-413f-452b-858a-0909bac3922f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ZTViNjRiMjNjODI0NGU3YWE5YzIzZGE3OWNlMWUyNzUvdGFibGVyYW5nZTplNWI2NGIyM2M4MjQ0ZTdhYTljMjNkYTc5Y2UxZTI3NV8xLTAtMS0xLTM0NDg5_b03a866d-74db-43fa-aad2-404b5aff64bc">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ZTViNjRiMjNjODI0NGU3YWE5YzIzZGE3OWNlMWUyNzUvdGFibGVyYW5nZTplNWI2NGIyM2M4MjQ0ZTdhYTljMjNkYTc5Y2UxZTI3NV8xLTItMS0xLTM0NDg5_f2b7e43e-2dec-40f6-851f-cbdcabf5601a">ARDX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ZTViNjRiMjNjODI0NGU3YWE5YzIzZGE3OWNlMWUyNzUvdGFibGVyYW5nZTplNWI2NGIyM2M4MjQ0ZTdhYTljMjNkYTc5Y2UxZTI3NV8xLTQtMS0xLTM0NDg5_3d8bee22-eea2-454b-af50-e2d92bdfb369">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjYw_04192855-de3a-43b3-822e-ed369c9752e9">&#9744;</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id9493d6b320c43bc9334024787663dbd_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;4, 2022, Ardelyx, Inc. (the &#8220;Company&#8221;) announced its financial results for the fiscal quarter ended June&#160;30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished under this Item 2.02 shall not be considered &#8220;filed&#8221; under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under&#160;the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered &#8220;filed&#8221; or incorporated by reference therein.</span></div><div id="id9493d6b320c43bc9334024787663dbd_10"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:58.5pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ardx-20220630xexhibit991.htm">Press release of Ardelyx, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id9493d6b320c43bc9334024787663dbd_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 4, 2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARDELYX, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Accounting Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ardx-20220630xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6be02e738f354b259589f2048d7bacb6_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:184px"></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit&#160;99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:112%">Ardelyx Reports Second Quarter 2022 Financial </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Results and Recent Business Highlights</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%"> Conference call scheduled for 4&#58;30 p.m. Eastern Time today</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">WALTHAM, Mass., Aug 4, 2022 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">- Ardelyx, Inc. (Nasdaq&#58; ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and financial results for the second quarter ended June&#160;30, 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8220;The second quarter marks a significant point of transition for Ardelyx as a commercial company,&#8221; said Mike Raab, president and chief executive officer of Ardelyx. &#8220;We are now three months into the launch of IBSRELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, for the treatment of IBS-C in adults, and see that the market is responding enthusiastically to this much-needed innovative therapy. We are building strong relationships with the treating community and, across GI practices. Our sales and marketing launch efforts are raising visibility and building a foundational demand for IBSRELA. Separately, the FDA assigned a date for the advisory committee to review our NDA for XPHOZAH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:174%;position:relative;top:-3.48pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">for hyperphosphatemia, and we look forward to the opportunity to highlight the strong data that support XPHOZAH and its potential to make a difference in the lives of patients with chronic kidney disease on dialysis.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Recent Business Highlights and Updates</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Spherix Global Insights, a company that publishes independent, syndicated monthly tracking research has included IBSRELA (tenapanor) as one of the key launches to follow in the GI space. Three months post-launch, Spherix reports that with respect to those GIs surveyed in its market research, two-thirds are aware of IBSRELA, 41% report use of IBSRELA, and 92% rate IBSRELA as either a substantial or moderate advance over currently available irritable bowel syndrome with constipation (IBS-C) therapies. In addition, those GIs surveyed reported that 31% of their patients may be candidates for treatment. Among those who have not yet used IBSRELA, 57% expect to use it within three months and an additional 21% expect to use within six months. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">The American Gastroenterological Association (AGA) announced their updated Clinical Practice Guideline on the &#8220;Pharmacological Management of Irritable Bowel Syndrome with Constipation.&#8221; The updated guideline includes IBSRELA in their IBS-C treatment recommendations.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">The company presented multiple posters at the Digestive Disease Week Conference (DDW 2022) in San Diego, CA on May 21-24, 2022, which included long term data demonstrating the impact of IBSRELA on abdominal pain and other abdominal symptoms&#59; effect of IBSRELA on treatment satisfaction, degree of relief, and quality of life&#59; and early onset of action in treating symptoms of irritable bowel syndrome with constipation. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">On June 21, 2022, the company announced that the U.S. Food and Drug Administration (FDA) informed the company that a meeting of the Cardiovascular and Renal Drugs Advisory Committee (Advisory Committee) is tentatively scheduled for November 16, 2022. As part of the Formal Dispute Resolution Request (FDRR), the Advisory Committee is being convened at the request of FDA&#8217;s Office of New Drugs (OND) in order to provide input regarding the clinical meaningfulness of the phosphate lowering effect observed in the company&#8217;s Phase 3 clinical program for XPHOZAH (tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">On June 30, 2022, the company announced a $20 million financing agreement with HealthCare Royalty Partners (HealthCare Royalty) based on the sale of its future royalties and sales milestones from Kyowa Kirin Co., Ltd (Kyowa Kirin), its collaboration partner in Japan, for the commercialization of tenapanor for hyperphosphatemia. Under the agreement, the company received from HealthCare Royalty a $10 million upfront payment and is entitled to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">an additional </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$5 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> following Kyowa Kirin's receipt of regulatory approval to market tenapanor for hyperphosphatemia in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Japan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">$5 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> in the event net sales in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Japan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> exceed a certain target level in 2025. In return, HealthCare Royalty will receive the royalty payments and commercial sales milestones that the company may earn under the license agreement with Kyowa Kirin.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Second Quarter 2022 Financial Results</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Cash Position&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> As of June&#160;30, 2022, the company had total cash, cash equivalents and investments of $81.0&#160;million, as compared to total cash, cash equivalents and investments of $116.7&#160;million as of December&#160;31, 2021.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Product Sales&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> Net product sales for IBSRELA were $1.6&#160;million during the quarter ended June&#160;30, 2022.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;padding-left:13.8pt">Collaboration Revenue&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> The company generated $1.0&#160;million in collaboration revenue for the quarter ended June&#160;30, 2022, as compared to $1.3&#160;million for the quarter ended June&#160;30, 2021. The decrease in collaboration revenue was primarily the result of the recognition of the previously received upfront payment from the 2019 research and collaboration agreement between the company and Kyowa Kirin </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">that was fully earned and recognized as revenue as of December 31, 2021. The decrease in collaboration revenue was partially offset by product supply revenue related to the manufacturing and supply of tenapanor and other materials for Kyowa Kirin pursuant to the 2017 license agreement between the company and Kyowa Kirin.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">R&#38;D Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#58; Research and development expenses were $9.7&#160;million for the quarter ended June&#160;30, 2022, a decrease of $16.3&#160;million, or 62.6%, compared to $26.0&#160;million for the quarter ended June&#160;30, 2021. Research and development expenses included non-cash stock compensation expense of approximately $1.0&#160;million and $1.1&#160;million in the quarters ended June&#160;30, 2022, and June&#160;30, 2021, respectively. The decrease in R&#38;D expenses is primarily the result of lower clinical study costs from the OPTIMIZE study, lower tenapanor manufacturing expenses due to the company&#8217;s capitalization of  costs associated with the production of IBSRELA to inventory, and lower expenses for research following the elimination of the company&#8217;s research function in the fourth quarter of 2021. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">SG&#38;A Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> Selling, general and administrative expenses were $18.9&#160;million for the quarter ended June&#160;30, 2022, a decrease of $1.3&#160;million, or 6.3%, compared to $20.1&#160;million for the quarter ended June&#160;30, 2021. Selling, general and administrative expenses included non-cash stock compensation expense of approximately $2.2&#160;million and $2.1&#160;million in the quarters ended June&#160;30, 2022, and June&#160;30, 2021, respectively. The decrease in selling, general and administrative expenses was primarily due to the timing of costs associated with preparing for and carrying out the commercial launch of IBSRELA. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Net Loss&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Net loss for the quarter ended June&#160;30, 2022 was $26.9&#160;million, or $0.19 per share, compared to $45.2&#160;million, or $0.45 per share, for the quarter ended June&#160;30, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:150%">Conference Call Details</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">The company will host a conference call today, August&#160;4, 2022, at 4&#58;30 p.m. ET to review its financial results and provide a business overview. To participate in the conference call via telephone, please register using </font><font style="color:#008ba6;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">this online form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at </font><font style="color:#008ba6;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">www.ardelyx.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. The webcast will be archived and available for replay for 30 days following the call.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">IMPORTANT SAFETY INFORMATION</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WARNING&#58; RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS</font></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">IBSRELA is contraindicated in patients less than 6 years of age&#59; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.</font></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">CONTRAINDICATIONS</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">WARNINGS AND PRECAUTIONS</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Risk of Serious Dehydration in Pediatric Patients</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old&#59; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years). </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Diarrhea </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">If severe diarrhea occurs, suspend dosing and rehydrate patient.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">MOST COMMON ADVERSE REACTIONS </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">The most common adverse reactions in IBSRELA-treated patients (incidence &#8805;2% and greater than placebo) were&#58; diarrhea (16% vs 4% placebo), abdominal distension (3% vs &#60;1%), flatulence (3% vs 1%) and dizziness (2% vs &#60;1%).</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">INDICATION </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Please see full Prescribing Information, including Boxed Warning, for additional risk information.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:150%">About Ardelyx, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx&#8217;s first approved product, IBSRELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:174%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:174%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium secretagogue program, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and&#47;or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:150%">Forward Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including Ardelyx&#8217;s current expectation regarding the timing of the Advisory Committee meeting to be convened to provide input regarding the clinical meaningfulness of the phosphate lowering effect observed in the Phase 3 clinical program for XPHOZAH, the potential receipt by Ardelyx of additional payments under the royalty financing agreement with HealthCare Royalty, and the potential for additional GIs to begin use of IBSRELA in the next three to six months as reported by the Spherix report. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the FDA&#8217;s regulatory process, uncertainties in the drug development and regulatory processes in Japan and uncertainties associated with the commercialization of drugs. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August&#160;4, 2022, and its future current and periodic reports to be filed with the Securities and Exchange Commission. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investor and Media Contacts&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Kimia Keshtbod </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">kkeshtbod&#64;ardelyx.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sylvia Wheeler</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wheelhouse Life Science Advisors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">swheeler&#64;wheelhouselsa.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Alex Santos</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wheelhouse Life Science Advisors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">asantos&#64;wheelhouselsa.com</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6be02e738f354b259589f2048d7bacb6_4"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ardelyx,&#160;Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:65.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,408</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,604</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,623</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,529</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,054</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,752</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid commercial manufacturing</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,793</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,058</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,202</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,610</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,913</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,277</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,373</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,264</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,366</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,857</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,748</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,591</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,042</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,617</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,610</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,913</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Derived from the audited financial statements included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6be02e738f354b259589f2048d7bacb6_7"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ardelyx,&#160;Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,005</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,477</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,862</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,124</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,201</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,255</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,741&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,145&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,016&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,732&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,215)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,832)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,022)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,837)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(787)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,533)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,302)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,932)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,187)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,001)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,341)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,938)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,189)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,009)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,344)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per common share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares used in computing net loss per share - basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,544,372&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,040,083&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,279,945&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,617,564&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ardx-20220804.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1392da93-4cce-4f51-9204-96af2cb97a3b,g:1f19f9d2-6f60-4abd-b179-525c41c41081-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ardx="http://www.ardelyx.com/20220804" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ardelyx.com/20220804">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220804_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220804_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ardelyx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ardx-20220804_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1392da93-4cce-4f51-9204-96af2cb97a3b,g:1f19f9d2-6f60-4abd-b179-525c41c41081-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_d133d4ba-01a9-4927-abd7-fd37f278863d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e7dc1f3a-11a4-46b4-9cf6-dfb25c59507e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0a1eb69a-510d-45d2-8d2e-76eea1fffb5d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_330bbbbc-ca43-4cba-a509-14e32406cb61_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1079bae1-641a-4544-9126-9056f0f7ee03_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ff8eb36e-435a-47e0-8144-73ee2b7ead62_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_86563ce8-c1d2-4735-894a-1df4f897bf0f_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_706b10d1-cf07-406d-a3ba-d2ebd67cfcaf_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3b29a80e-384d-496a-b131-eb1893946b6f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_43a0368d-9403-49bb-bcee-6632c3defd48_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_eec2c22b-af86-4443-8aed-7d1fd6c1c254_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_fc229692-052d-4f98-98d1-45f7c8acff03_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_24989cc1-6151-4694-acf9-e762d098d411_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4e742a63-4896-46c7-9b8d-f82933200882_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f535cb17-211a-41e9-9de6-6b4aeea36b43_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_afc1f3a4-16c4-49f8-a11d-94d09bcb9afd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5ec01f06-3cbd-4a79-92b2-d1ffa70cb9d4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_29c4f75b-37cb-4cb9-b728-195242f525ad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_77465af4-9b7b-4cce-b109-d9227a8a689c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dbb7dc20-dd24-4b85-9eb5-142a601a9f8b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_af8a3656-964e-46b3-8d18-f14fcc4fa893_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d8d75165-5a17-41d9-bb9c-b6f6cf5b95ad_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e1861abf-0f72-4312-a16a-da4b22b2e9fa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ardx-20220804_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1392da93-4cce-4f51-9204-96af2cb97a3b,g:1f19f9d2-6f60-4abd-b179-525c41c41081-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/Cover" xlink:type="simple" xlink:href="ardx-20220804.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fca9267a-b2a8-470e-876d-2595600741ba" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_DocumentType_fca9267a-b2a8-470e-876d-2595600741ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f16f3707-a217-4627-96d0-91849d0636ac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_DocumentPeriodEndDate_f16f3707-a217-4627-96d0-91849d0636ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_49dbc706-188e-48ea-b3b0-f20618dc276f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityRegistrantName_49dbc706-188e-48ea-b3b0-f20618dc276f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_75aaf3cc-176b-42e0-b71c-a0b3e301b5fe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityIncorporationStateCountryCode_75aaf3cc-176b-42e0-b71c-a0b3e301b5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ed099e2a-303d-4ab0-8790-382978228681" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityFileNumber_ed099e2a-303d-4ab0-8790-382978228681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_496c8791-aada-45b8-9da8-962d0958f714" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityTaxIdentificationNumber_496c8791-aada-45b8-9da8-962d0958f714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_40bbfa14-875d-4305-b40e-7c1b65c4ed4e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityAddressAddressLine1_40bbfa14-875d-4305-b40e-7c1b65c4ed4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_244adc15-a2d1-4b69-a137-66f5700235f7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityAddressAddressLine2_244adc15-a2d1-4b69-a137-66f5700235f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0e344424-5f4c-4722-a6d2-3d140ed90c66" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityAddressCityOrTown_0e344424-5f4c-4722-a6d2-3d140ed90c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3e9cc340-a358-4bac-9bca-c16750fa537d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityAddressStateOrProvince_3e9cc340-a358-4bac-9bca-c16750fa537d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e3b666a9-32cc-470c-a7e3-6b0e96f17a36" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityAddressPostalZipCode_e3b666a9-32cc-470c-a7e3-6b0e96f17a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0dc323b0-0a66-4db2-b770-d091b5faedd7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_CityAreaCode_0dc323b0-0a66-4db2-b770-d091b5faedd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_52533973-76a7-4b0c-9018-e61f521b4097" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_LocalPhoneNumber_52533973-76a7-4b0c-9018-e61f521b4097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_ad419273-dc67-4076-8a49-813c76f18658" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_WrittenCommunications_ad419273-dc67-4076-8a49-813c76f18658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c3b5b2ac-c323-400f-a873-6ed7ed76eb95" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_SolicitingMaterial_c3b5b2ac-c323-400f-a873-6ed7ed76eb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_3b1b957d-b663-4f84-825d-b69a593ed09b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_PreCommencementTenderOffer_3b1b957d-b663-4f84-825d-b69a593ed09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ac00c7cb-649f-4041-97a2-23ffbf4133e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ac00c7cb-649f-4041-97a2-23ffbf4133e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a8dbc6ba-44e2-49a5-b557-6026bb33f129" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_Security12bTitle_a8dbc6ba-44e2-49a5-b557-6026bb33f129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2d2cb831-0bd8-47a2-a18a-c9bd64d384d9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_TradingSymbol_2d2cb831-0bd8-47a2-a18a-c9bd64d384d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_44b85b77-6c9b-47bd-b2d3-586bb9cc90f6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_SecurityExchangeName_44b85b77-6c9b-47bd-b2d3-586bb9cc90f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1ba76461-68fe-4f75-bc51-abdfb6dfb811" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityEmergingGrowthCompany_1ba76461-68fe-4f75-bc51-abdfb6dfb811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f7423bc0-e9dc-40b8-9f94-cd10352aa391" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_EntityCentralIndexKey_f7423bc0-e9dc-40b8-9f94-cd10352aa391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a991184b-488b-4b5e-9206-c89bc1e86556" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b384b7b2-819e-4300-9007-5441277bcc09" xlink:to="loc_dei_AmendmentFlag_a991184b-488b-4b5e-9206-c89bc1e86556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ardx-20220804_g1.jpg
<TEXT>
begin 644 ardx-20220804_g1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K &L# 2(  A$! Q$!_\0
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%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +,# 2(  A$! Q$!_\0
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I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140156924378112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  04,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARDELYX, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1303944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 FIFTH AVE.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">WALTHAM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">745-1700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARDX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001437402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ardx-20220804_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ardx-20220804.xsd" xlink:type="simple"/>
    <context id="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2022-08-04</startDate>
            <endDate>2022-08-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF80L2ZyYWc6NGY1NGMzMzZhOTJhNGUwMWI2OTkyMGViZGU1NDZmYjIvdGFibGU6NTI1N2NhYTVhYmViNGFlODgyYzI0MWIwZGMxYzE1OTcvdGFibGVyYW5nZTo1MjU3Y2FhNWFiZWI0YWU4ODJjMjQxYjBkYzFjMTU5N18yLTEtMS0xLTM0NDg5_f58008ff-a9ce-4e69-8f84-935af6fe5857">0001437402</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF80L2ZyYWc6NGY1NGMzMzZhOTJhNGUwMWI2OTkyMGViZGU1NDZmYjIvdGFibGU6NTI1N2NhYTVhYmViNGFlODgyYzI0MWIwZGMxYzE1OTcvdGFibGVyYW5nZTo1MjU3Y2FhNWFiZWI0YWU4ODJjMjQxYjBkYzFjMTU5N18zLTEtMS0xLTM0NDg5_2771d50d-04d9-412f-a452-23fd9c15cd02">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjYx_ac66504e-3b4e-49ef-b47c-4b9600169cda">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8yMzE_b973efd0-b09d-4b26-836f-d81350e71f28">2022-08-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjU0_600fb92d-0917-428c-8e76-018848175759">ARDELYX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6OTBmNTc2Mzk3ZTgzNDNiN2IzMTQ4ODI4NzZlNjQ5ODEvdGFibGVyYW5nZTo5MGY1NzYzOTdlODM0M2I3YjMxNDg4Mjg3NmU2NDk4MV8wLTAtMS0xLTM0NDg5_79a98c5a-c7b5-44da-b5a8-d68109127fb4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6OTBmNTc2Mzk3ZTgzNDNiN2IzMTQ4ODI4NzZlNjQ5ODEvdGFibGVyYW5nZTo5MGY1NzYzOTdlODM0M2I3YjMxNDg4Mjg3NmU2NDk4MV8wLTEtMS0xLTM0NDg5_b5cf26e1-5f21-496b-914e-29f8171430cd">001-36485</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6OTBmNTc2Mzk3ZTgzNDNiN2IzMTQ4ODI4NzZlNjQ5ODEvdGFibGVyYW5nZTo5MGY1NzYzOTdlODM0M2I3YjMxNDg4Mjg3NmU2NDk4MV8wLTItMS0xLTM0NDg5_bf809a2e-fc49-4996-a11c-607aa3f150e7">26-1303944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjU2_b0070d5e-e3d7-4bb2-907f-7935f2e96d50">400 FIFTH AVE.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjU3_7843159d-6cac-43a1-90c0-d4e40fcc91e2">SUITE 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjYy_e7acb292-af08-4c40-8b45-f3fef8d1fd0f">WALTHAM</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjYz_b2d6ab0f-d25e-4b97-9644-1d823f45a1a0">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjY0_b5059173-d643-4367-8ea2-3520d1c5c997">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjU5_babbb14e-fa24-4d59-a8bd-4caeab27d88f">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjY1_f5b7125f-f52c-4db3-9a14-3dc129d5f50c">745-1700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ODAxZmEwMTE4MzM3NDY2N2E2Yzg0OThlY2ZlYzA0NWYvdGFibGVyYW5nZTo4MDFmYTAxMTgzMzc0NjY3YTZjODQ5OGVjZmVjMDQ1Zl8wLTAtMS0xLTM0NDg5_655d760f-b946-4afd-80ea-314993414704">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ODAxZmEwMTE4MzM3NDY2N2E2Yzg0OThlY2ZlYzA0NWYvdGFibGVyYW5nZTo4MDFmYTAxMTgzMzc0NjY3YTZjODQ5OGVjZmVjMDQ1Zl8xLTAtMS0xLTM0NDg5_be9a9035-8ea4-43e1-a86c-547077b3255c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ODAxZmEwMTE4MzM3NDY2N2E2Yzg0OThlY2ZlYzA0NWYvdGFibGVyYW5nZTo4MDFmYTAxMTgzMzc0NjY3YTZjODQ5OGVjZmVjMDQ1Zl8yLTAtMS0xLTM0NDg5_5a0146d4-192b-44fc-985e-b42e71026533">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ODAxZmEwMTE4MzM3NDY2N2E2Yzg0OThlY2ZlYzA0NWYvdGFibGVyYW5nZTo4MDFmYTAxMTgzMzc0NjY3YTZjODQ5OGVjZmVjMDQ1Zl8zLTAtMS0xLTM0NDg5_b32c61e1-413f-452b-858a-0909bac3922f">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ZTViNjRiMjNjODI0NGU3YWE5YzIzZGE3OWNlMWUyNzUvdGFibGVyYW5nZTplNWI2NGIyM2M4MjQ0ZTdhYTljMjNkYTc5Y2UxZTI3NV8xLTAtMS0xLTM0NDg5_b03a866d-74db-43fa-aad2-404b5aff64bc">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ZTViNjRiMjNjODI0NGU3YWE5YzIzZGE3OWNlMWUyNzUvdGFibGVyYW5nZTplNWI2NGIyM2M4MjQ0ZTdhYTljMjNkYTc5Y2UxZTI3NV8xLTItMS0xLTM0NDg5_f2b7e43e-2dec-40f6-851f-cbdcabf5601a">ARDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGFibGU6ZTViNjRiMjNjODI0NGU3YWE5YzIzZGE3OWNlMWUyNzUvdGFibGVyYW5nZTplNWI2NGIyM2M4MjQ0ZTdhYTljMjNkYTc5Y2UxZTI3NV8xLTQtMS0xLTM0NDg5_3d8bee22-eea2-454b-af50-e2d92bdfb369">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5NDkzZDZiMzIwYzQzYmM5MzM0MDI0Nzg3NjYzZGJkL3NlYzpkOTQ5M2Q2YjMyMGM0M2JjOTMzNDAyNDc4NzY2M2RiZF8xL2ZyYWc6NWZlYTJhM2JmNzljNDhmZWEyMmRkOTlhMTdjMmRkOGYvdGV4dHJlZ2lvbjo1ZmVhMmEzYmY3OWM0OGZlYTIyZGQ5OWExN2MyZGQ4Zl8xMjYw_04192855-de3a-43b3-822e-ed369c9752e9">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZZ!$U13@XC;]K+C63$#')$DN]FZ6U5+A0DL:9PQ#JCS?Q0U[)F,><LW%BCQ
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%
M  @ BX $520>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>
M+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2
M*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+B
MRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#
M!!0    ( (N !%5ED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM
M;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL
M>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE
M@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J
M1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;
M&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=
M560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^Q
MO-9.&G_FB^$_7G\!4$L! A0#%     @ BX $50=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "+@ 15
M^##GZ>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "+@ 15F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (N !%5]*01;4@0
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M2P$"% ,4    " "+@ 15)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "+@ 1599!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ardx-20220804.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ardx-20220804.htm">ardx-20220804.htm</File>
    <File>ardx-20220630xexhibit991.htm</File>
    <File>ardx-20220804.xsd</File>
    <File>ardx-20220804_lab.xml</File>
    <File>ardx-20220804_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ardx-20220804_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ardx-20220804.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ardx-20220804.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ardx-20220804_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ardx-20220804_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ardx-20220804.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ardx",
   "nsuri": "http://www.ardelyx.com/20220804",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220804.htm",
      "contextRef": "i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.ardelyx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220804.htm",
      "contextRef": "i7da3d4207f3f4d73aa8b0ba0f940df3d_D20220804-20220804",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-22-021051-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-021051-xbrl.zip
M4$L#!!0    ( (N !%4^"@.^@B$  -MF 0 <    87)D>"TR,#(R,#8S,'AE
M>&AI8FET.3DQ+FAT;>T]:W?:2++?[Z_H3289YQR!D7C;V9S#V,Z,=Q+;BSTW
MN_OEGD9JH-="TNB!S?SZ6]7=$@)DFZ<!HSF[=@QZ5->[JJNJ/__M_/KL[M\W
M%Z0?#FQR\\<OWR[/R+O"\?&/\MGQ\?G=.?GM[OLW4BF6='+G4R?@(7<=:A\?
M7UR](^_Z8>B='!\_/#P4'\I%U^\=W[6/\5&58]MU U:T0NO=E\_X"?QDU/KR
M/Y__5BB0<]>,!LP)B>DS&C*+1 %W>N2'Q8)[4BBHJ\Y<;^3S7C\D1LDPR _7
MO^=#*K\/>6BS+_%S/A_+OS\?BY=\[KC6Z,MGBP\)M_[^CM<ZK&2P>KG1+5<K
M':/:K#::7:-4:5CU#C4[M?_3 <ACN%S>$X0CF_W]W8 [A3[#]Y]4C&*]ZH6G
M#]P*^R=ZJ?3AW>2EU._!U:'KP9=P7<@>PP*U><\Y,0$\YL/E?- CU X!G 'M
ML?\KT>)_O=X[$OCFS$?RH?&[F][CJ7I!QPU#=W""H R9'W*3VNHUXHWRZQC*
M1L5[3-8UN[JG018XASN[+E!(76ZZMNN?O"^)_T[QFT*7#K@].OGYC@]80*[8
M VF[ ^K\K 7 )X6 ^;PK+PSX7^Q$-^ EXL\'N:XZ/,?F#HMQK!N(U8O'/N_P
M\.-[O58Z;3:+^N=CO"EC 5DX7B_$E9<@U@V N.5;S!X]DC;S7#\,R"TS7<<B
M_XRH#T!)UOW*'>J8G-IDEY<C"-!F063#,BBLH<T0%/(+2B<+ O(;7&?CM<',
M,B2P('G^ERTN,>$Q\<03'L+;S(E%5Z877:K#HD'5.%WF,\=D!&3*)H'99U9D
M@V;JNCZI?'Q?;9R62\0K#HKD@@8 NT,0)A*Z%AVM%1O9=[VZ--8K@)<?K6]W
MO[6^:^0[#8*B1EI1CU0TR=,QB)N%:X9> JX"45*GD4O'+)*C*QI8]$]!)M)J
MG__KDT8HZ7#7ZU-_0$T6"5U)3'?@46<$1(T<"XC[P,,^7#C@00!F#8A)+!Z8
M+NA6C5ALR&S7$X( ]PV8CP(,0!+N..Z0AGS(2)?[05@ /6K:@"$R8!8W459(
MV*<A_,D -4!AWH77 YHB9\!">15 XS!F!9ID(>(+]0$P=6)IBSP+;*.4Q&ZB
M0'PEG\B789^10*J;/Y6Z86)=_X@<)E5HN23)59S5/-MDMVRR?GS?,(S2Z=WL
MLL!:W0,F)I#IN1Q^NET2)HZ)P$JLD"G>,*9<3'Q-O$4_)0'E%OG.[QEI4]K1
MB >HY18J/$'R/F==PAZ9&0E*NUUX+4 "[U,O*!(%[P]&J,^(XSX 17S&R !6
MV@^ 3X"AD$8VC1RSC[=>_G+;OOC6VHCLU(N-.;!\ZKD25R<^LP43GZ(/4*@4
MC5FOHD,#A@] TL#-I]N4>2UA^1"=1N$^2HP6S@#5A%HH%YH@7@!$$!*(ER/O
M@-3Q &7' ZY"5Q/N[H.@@2K'Y=HC(D@%UPPBLU] R00Q2@DZ/,BGWJA(%+$[
M$;?%@X+0=^&71*;K!'WN!5*O)*#B9<B'D</#$<('0)J^"R+^ZR5P'34!!A84
MR77D U/:2N0EV'BO8A_6[0H' U_O4RX\YB'\ZG!;/7<,%94JCDIO'7390&@1
M0*#BP"+X*1[U0<'8(TV ^O6\!2*# @8KIP1U3X)Q:L&+7'\DEL'#$-'KPIJ'
M'&CK MA7<#->_*^;WZ[_T_HMY^\4W+5BI;X"X.5BI?$<Y%LUQ$CS_LACOM=W
M S"V(1MP*F7P ?2>Z]XC6SQ0WR)*%[H>VCDI"O!1/W8II3&3P@2\1Z7\!I&X
M/.8K\6 .,N"Y(4@P:G5XQH""#@>.Y=W8AP-U(/0N(#% )>$!/N%Z)9AF']["
M37+/+8>-T.0SP"8!\V'!$T<!#XK*1NR4S<QVT9[VT06R_I!.Q%(>JD<M5"8%
MFW7A;8TX2.0.&LF3 GZR\2CQ&4>AMD5S=#J)FW)1X.+6 RO!'\FOMML!UKP$
MKP0)H4D_1'B>@JN]J&/SH,_01;"8QP1"-1*,''0,T0D4'@1:); .]US8%V!2
M'ZQ G^)=IAVA@5+*G!R!-%!XONM_0K?'=9CPBT $[H'!I?U I]0%:;1M\%.4
M@(#]"3QPCXOD+NVX@"8*"_(NC<2+\E5\*U8@Y C-*3-#*=EN@(\+0&+](1L)
MXRDD55G?&'ZP-0]N 2RM;TE+1A_PY]@UTDA%_Z!>1J)@\BODZ*8!7Z-QBA</
M"V8<[3/ZAU$G"*G4#*":!J[%Q+5@P"@J!G3MB1GYH"9"0"\=4F[3C@T:P_<A
M6L1_==P'9@M:^"X$>%)C@&$/N2?,*3D2+L<GY1)PM-R7Z'Y80GMK6;A(G'N!
MO#(L4)*'^V/5-( @H(/A)S"!=/R%]8U]G2)I#5 WRJ<_]$%UTB$ZG2$9,8$I
M:XRG:OT#N*XQ<1"+7-),T#U%:40H'0,/6#/TZ5O5?0'P@+PK(Y;(5<:2*@-C
MG19$*!C2D%\I&D"1# "0>B)(; 6!"^&+Y+S6KRT0</!*030%-R$'R3C1(F?P
M1G'+C7(IR:\1Q#,(!]HVE'<5L-S(J#AYQW?JT!Y+/.I$%'X1HG [(0IG*5&(
MS23!5<1@])*7*C45))(JM0[WE=,^]N-])N(TY; &Q2?Y:RH?.^LR/96A59G3
MTO@6V@E<.PIG;WG2-*9_]OTQR_=8H0-+N2_0+E#NA-H/=!2\6S27_,)K<R%;
M3<AB XQ1/DH8V%B(%[D';([FCOF@#*43>LY[+!!!W[GR#'\P=I].$1Z=G_\0
M695/R-*W(+GGG/5<C9RU4-*^@R8W](*A,F4::&L.ECNQVK;0X\P?2$<7@C.4
M*5\&B@@!!U#-,&7Y\*FT8[G 1B"N'L5P%S2W*ZU>\D4P&GC Y<'']]7F*<:+
M;.8I8YD+X'U!%S4%&BV+]= LP,4@2IQUI:W],Z(BMH2/;=YE\KGX!=AR,)\
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ME7:1=6]\UXH@;+Y%Q;M]UKT""^,ID*0M2-5L$(CT&3!,L3;)+E;DQVF#%\O
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M-&$MH3JJ;HBYE758F+UB@JI6,\J;L*MO'W,EX\!MCI@F?G 6IZ)5C69N<);
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MP^[LE'NF:6A,8MV%/\R1/G:9Y6'F.B;8E:;C"5[:LO%?=XWS-S;^R=EX/2T
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M3+(+?IXZ(_N#JJ6^;EMD*U<6T@M(7-R/E$MW:@5F?/_)K*Y\<D)ZQ15/U<P
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M%K\^[Z#B1F(._X%_'&[]/U!+ P04    " "+@ 15B94\>6D"  !K!P  $0
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M5+I0^DTWX. U-5$[^,E ^^-_!U!+ P04    " "+@ 15"]HR^Y,*   180
M%0   &%R9'@M,C R,C X,#1?;&%B+GAM;,V<76_;.!:&[_LKM-F;76!8BQ1%
MB47;03?3#HK-M$6;HH-=+ Q^)L(X4B K3?+OEY+M1(HEFY1L1471N#%]^)[7
M>G@H4M+K7^^N%MY/E2^3+'US E_Z)YY*12:3].+-R??S#R ^^?7MBQ>O_P;
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MWVW1B/H\MUJT)=9YGT5KX[[@?U47R;+(65I\,M_U/%3"A]HG(!!< LPB,Y%
M' $)M6:1;Z"7ULO3;1U,%/='D5ZITA7R)R;:\MW?FG'0MG6E!]#MJ0]@^4G
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MW2C[WX'V<=JR[;>1TX@TWDY.6P*-K9S6!@,+Q9=L6;#%?Y+K:BN!Z9@%)"2
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M.3DQ+FAT;5!+ 0(4 Q0    ( (N !%63760:'!0  +V$   1
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H>"TR,#(R,#@P-%]P<F4N>&UL4$L%!@     &  8 D $  !U4      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
